Essex Investment Management Co. LLC decreased its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 13.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 173,799 shares of the company's stock after selling 26,717 shares during the period. Essex Investment Management Co. LLC owned approximately 0.24% of Kiniksa Pharmaceuticals worth $3,438,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently made changes to their positions in KNSA. Quarry LP acquired a new stake in Kiniksa Pharmaceuticals during the third quarter valued at approximately $50,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after acquiring an additional 1,004 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth $189,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Kiniksa Pharmaceuticals in the 4th quarter worth $258,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Kiniksa Pharmaceuticals during the third quarter valued at $268,000. Institutional investors and hedge funds own 53.95% of the company's stock.
Kiniksa Pharmaceuticals Price Performance
Kiniksa Pharmaceuticals stock traded down $0.34 during mid-day trading on Thursday, hitting $22.16. The company's stock had a trading volume of 500,058 shares, compared to its average volume of 406,238. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15. The company has a market cap of $1.61 billion, a PE ratio of -158.27 and a beta of 0.48. The firm's 50 day moving average is $19.90 and its 200 day moving average is $22.23.
Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). The company had revenue of $122.50 million during the quarter, compared to analysts' expectations of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. Kiniksa Pharmaceuticals's revenue for the quarter was up 46.9% compared to the same quarter last year. During the same period last year, the company earned $0.35 earnings per share. As a group, analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.
Insider Buying and Selling at Kiniksa Pharmaceuticals
In other news, COO Eben Tessari sold 14,000 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the transaction, the chief operating officer now directly owns 81,975 shares of the company's stock, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 54.57% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently weighed in on KNSA shares. Wedbush reiterated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday. They issued a "buy" rating and a $40.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $37.17.
View Our Latest Stock Analysis on Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Profile
(
Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Read More
Before you consider Kiniksa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals wasn't on the list.
While Kiniksa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
